Meeting Banner
Abstract #2087

Pre-treatment tumoral levels of total choline, glycine, and Glx predict overall survival in diffuse intrinsic pontine glioma

Ritambhar Burman1, Payton Goyke1, Silu Zhang1, Yu Wang2, Esther Pavao1, Sydney Somogyi3, Soniya Pinto1, Yiping Fan4, Matthew Scoggins5, Wilburn E Reddick1, Arzu Onar-Thomas2, Jason Chiang6, Christopher Tinkle7, and Puneet Bagga1
1Radiology, St. Jude Children's Research Hospital, Memphis, TN, United States, 2Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, United States, 3Eastern Tennessee State University, Johnson City, TN, United States, 4Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN, United States, 5Psychology and Biobehavioral Sciences, St. Jude Children's Research Hospital, Memphis, TN, United States, 6Pathology, St. Jude Children's Research Hospital, Memphis, TN, United States, 7Radiation Oncology, St. Jude Children's Research Hospital, Memphis, TN, United States

Synopsis

Keywords: Cancer, Spectroscopy, DIPG, Pediatrics, survival

Motivation: Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive and lethal pediatric brainstem cancer that is often diagnosed by imaging due to risks of biopsy.

Goal(s): We aimed to noninvasively identify tumor metabolites that provide insight into pathways associated with overall survival in DIPG.

Approach: We used 2D-CSI to map tumor metabolites prior to radiotherapy in 43 pediatric patients with DIPG. A data processing pipeline was developed to identify tumor masks and extract reliable metabolite information from tumor voxels.

Results: Elevated total choline, glycine, and Glx had significantly high Cox proportional hazard ratios, indicating their potential as predictors of survival in DIPG patients.

Impact: Mapping tumor metabolites using 2D-CSI prior to treatment may predict overall survival in patients with diffuse intrinsic pontine glioma. This approach may offer valuable prognostic information, potentially guiding personalized therapeutic strategies in this highly aggressive and lethal pediatric brainstem cancer.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.

Keywords